Compare Abbott Laboratories (ABT) vs Capital One Financial Corp. (COF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Capital One Financial Corp. — how do they compare? Abbott Laboratories trades at $95.38 (market cap $166.94B), while Capital One Financial Corp. trades at $192.57 (market cap $124.98B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | COF | |
|---|---|---|
Market Cap | $166.94B | $124.98B |
Sector | Health | Financials |
52-Week High | $136.62 | $257.94 |
52-Week Low | $82.57 | $176.10 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Capital One (COF) trades at $202.89, down 1.09% with a bullish technical outlook despite recent earnings misses. The stock shows strong analyst support with 62.5% buy ratings and a $252 consensus target, representing 24% upside. Recent financials reveal revenue growth to $53.43B in 2025 but declining net margins to 4.59%, while cash flow improved significantly to $18.42B. The company faces regulatory scrutiny and credit risk concerns but benefits from Discover integration and expanding software offerings.
COF presents a compelling risk-reward profile with substantial upside to analyst targets, though investors must weigh strong institutional support against margin pressure and economic sensitivity. The Discover acquisition provides long-term scale advantages, but near-term performance depends on credit quality stability and successful integration execution amid potential recessionary headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →
